Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P63220
UPID:
RS21_HUMAN
Alternative names:
40S ribosomal protein S21
Alternative UPACC:
P63220; P35265
Background:
The Small ribosomal subunit protein eS21, alternatively known as 40S ribosomal protein S21, plays a pivotal role in the assembly of the small ribosomal subunit. This protein is integral to the ribosome, a complex essential for protein synthesis within the cell, as highlighted in multiple studies (PubMed:23636399, PubMed:25901680, PubMed:25957688).
Therapeutic significance:
Understanding the role of Small ribosomal subunit protein eS21 could open doors to potential therapeutic strategies.